论文部分内容阅读
目的为揭示异常的可变剪接在肿瘤中发挥的作用,着重研究急性髓性白血病(AML)与慢性髓性白血病(CML)内显著差异的可变剪接事件以及剪接异构体。方法基于CML(K562)和AML(THP1、HL-60)细胞系的全转录组测序数据,在全基因组范围内采用Top Hat、MATS和Cufflinks计算识别可变剪接事件、重构剪接异构体和分析其差异表达。结果在AML和CML细胞间识别的130个基因在CML细胞系中特异性高表达,80个基因在AML两株细胞系内均表达上调。在CML与AML之间识别了337个差异表达的剪接异构体以及35个差异可变剪接事件。结论 AML与CML细胞系间存在显著差异的可变剪接事件和剪接异构体。白血病相关的可变剪接事件可作为其潜在的标志物或药物靶标。
Objective To reveal the role of aberrant alternative splicing in tumors, with a focus on alternative splicing events and splicing isomers that are significantly different in acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML). Methods Based on whole-transcriptome sequencing data of CML (K562) and AML (THP1, HL-60) cell lines, top Hat, MATS and Cufflinks calculations were used to identify alternative splicing events, reconstitute splicing isoforms and Analysis of its differential expression. Results 130 genes identified between AML and CML cells were highly expressed in CML cell lines, and 80 genes were up-regulated in both AML cell lines. 337 differentially expressed splice isoforms and 35 differential alternative splicing events were identified between CML and AML. Conclusion There are significant differences between AML and CML cell lines in alternative splicing events and splicing isoforms. Leukemia-associated alternative splicing events can serve as potential markers or drug targets.